ARA290 (Cibinetide)

Cibinetide Ara 290 Research and Mechanism

Cibinetide ara 290 is an 11-amino-acid synthetic peptide engineered from the tissue-protective helix B surface region of erythropoietin. According to research data from Luxara Labs, it was designed to activate the innate repair receptor (IRR), a heteromeric EPOR2-CD131 complex, without stimulating classical erythropoiesis.citeweb_search:20#2 This selective receptor targeting distinguishes cibinetide ara 290 from native erythropoietin, which activates both the erythropoietic EPOR homodimer and the protective IRR.

Research published in PMC demonstrated that cibinetide ara 290 improved glucose control in type 2 diabetes subjects with small fiber neuropathy, with significant reductions in HbA1c and improvements in the cholesterol-HDL ratio.citeweb_search:20#1 A separate study in PMC showed that chronic ARA290 treatment in aged rats mitigated cardiac inflammation, reduced NF-kappaB activation, enhanced autophagy flux, and preserved left ventricular ejection fraction.citeweb_search:20#4 Another study in PMC demonstrated renoprotective effects in porcine ischemia-reperfusion models, with improved glomerular filtration rate and reduced interstitial fibrosis.citeweb_search:20#0 It is critical to emphasise that cibinetide ara 290 is not approved by the TGA or FDA for human use. It is sold strictly for in vitro and laboratory research use only.

Ara 290 Cibinetide FDA Approval Status

Ara 290 cibinetide fda approval status remains investigational. According to regulatory tracking data, cibinetide has completed Phase 2 trials for diabetic neuropathy and macular edema but has not advanced to Phase 3 completion or received FDA approval.citeweb_search:20#2 The peptide is categorised as a repair-oriented research compound with published human evidence limited to specific research populations. For laboratories tracking pharmaceutical development pipelines, cibinetide ara 290 represents a mid-stage investigational compound with tissue-protective signalling as its primary research domain.

Cibinetide Ara 290 Dosage and Reconstitution

Cibinetide Ara 290 Dose for Research Protocols

For laboratory research, cibinetide ara 290 is typically supplied as a 10mg lyophilised powder. According to clinical trial data, human studies have used 4mg subcutaneous self-administration for 28 days.citeweb_search:20#1 Preclinical models have used doses ranging from 0.5mg per kg to 10nmol per kg depending on the research context. For in vitro applications, working concentrations of 100nM are common reference points for studying Schwann cell NLRP3 inflammasome inhibition and neuroinflammatory modulation.citeweb_search:20#3 Gently swirl the vial until fully dissolved. Do not shake vigorously. Allow the solution to settle at room temperature before aliquoting.

Reconstitution Guide

Remove the vial from freezer storage and allow it to equilibrate to room temperature for 15 to 20 minutes. Draw 1.0 to 2.0mL of bacteriostatic water into a sterile syringe and inject slowly down the inner vial wall to minimise foaming. Gently swirl until fully dissolved. Label with the reconstitution date and store at 2 to 8 degrees C protected from light. Use within 14 to 21 days. Do not freeze reconstituted solution.

How Cibinetide Ara 290 Compares to Other Research Compounds

Cibinetide Ara 290 vs Erythropoietin

Erythropoietin (EPO) is a 165-amino-acid glycoprotein hormone that stimulates red blood cell production through classical EPOR homodimer signalling. Cibinetide ara 290 is an 11-amino-acid peptide that selectively activates the innate repair receptor (EPOR2-CD131) without stimulating erythropoiesis. According to comparative research data, EPO carries thrombosis risk and elevated blood viscosity at supraphysiologic doses, while cibinetide ara 290 avoids these hematopoietic adverse effects.citeweb_search:20#2 EPO is approved for anaemia treatment; cibinetide ara 290 remains investigational. For researchers studying tissue-protective signalling without erythropoietic complications, cibinetide ara 290 provides a selective tool.

Cibinetide Ara 290 vs BPC-157

BPC-157 is a synthetic gastric pentapeptide primarily researched for tissue regeneration, angiogenesis, and gut healing through growth factor modulation. Cibinetide ara 290 is an erythropoietin-derived peptide that activates innate repair receptor signalling for tissue protection and anti-inflammatory effects. BPC-157 works through VEGF and NO pathways, while cibinetide ara 290 works through the EPOR2-CD131 complex and downstream Akt survival signalling. BPC-157 is studied for musculoskeletal and gastrointestinal repair, while cibinetide ara 290 is studied for neuropathy, cardiac protection, and renal ischemia-reperfusion. They serve different research purposes.

Cibinetide Ara 290 vs MOTS-c

MOTS-c is a mitochondrial-derived peptide that activates AMPK and regulates cellular energy homeostasis through metabolic stress response. Cibinetide ara 290 is an erythropoietin-derived peptide that activates innate repair receptor signalling for tissue protection. MOTS-c is studied for metabolic adaptation and exercise mimetics, while cibinetide ara 290 is studied for tissue protection, inflammation modulation, and nerve repair. These are entirely different research categories with no mechanistic overlap.

Cibinetide Ara 290 vs 5 Amino 1mq

5 amino 1mq is a small molecule NNMT inhibitor studied for metabolic regulation through NAD+ and SIRT1 pathways in adipose tissue. Cibinetide ara 290 is a peptide-based innate repair receptor agonist studied for tissue protection and anti-inflammatory effects. 5 amino 1mq addresses cellular energy balance; cibinetide ara 290 addresses tissue repair signalling. They are not interchangeable research compounds.

Cibinetide Ara 290 vs AOD-9604

AOD-9604 is a modified HGH fragment studied for direct lipolysis via beta-3 adrenergic receptor pathways. Cibinetide ara 290 is an erythropoietin-derived peptide with no lipolytic mechanism. AOD-9604 is positioned for fat metabolism research, while cibinetide ara 290 is positioned for tissue protection and repair signalling. They are entirely different research compounds.

Cibinetide Ara 290 vs Hgh Fragment 176 191

Hgh fragment 176 191 is a peptide fragment targeting the lipolytic domain of human growth hormone, studied for fat metabolism without IGF-1 effects. Cibinetide ara 290 is an erythropoietin-derived peptide with no structural relationship to growth hormone. Hgh fragment 176 191 is investigated for subcutaneous fat reduction, while cibinetide ara 290 is investigated for tissue protection and nerve repair. They are entirely different research tools.

Product Specifications

Purity and Analysis

• Content: 10mg lyophilised powder
• Sequence: 11-amino-acid peptide derived from erythropoietin helix B surface
• CAS Number: 1208243-50-8
• PubChem CID: 91810664
• Molecular Formula: C51H84N14O21S2
• Molecular Weight: 1269.4 g/mol
• Purity: Greater than or equal to 98% by HPLC
• Appearance: White to off-white lyophilised powder
• Source: Synthetic, manufactured via solid-phase peptide synthesis

Each batch is independently tested. Request the Certificate of Analysis (COA) for your specific batch number to verify purity, mass spec, and chromatography data.

Storage and Handling

• Lyophilised storage: -20 degrees C, protected from light and moisture
• Shelf life (unreconstituted): 24 months when stored correctly
• Handling: Use sterile technique. Avoid repeated freeze-thaw cycles

Shipping and Returns

We ship cibinetide ara 290 from our Australian facility via express domestic courier. Orders placed before 2:00 PM AEST dispatch the same business day. All orders are packaged in insulated, discreet packaging with cold-chain protection where required.

• Minimum order: $200 AUD
• Free shipping: Orders over $200 AUD
• Flat rate: $15 AUD for orders under $200
• Delivery time: 1 to 5 business days Australia-wide
• Returns: Unopened vials may be returned within 30 days of delivery for store credit or replacement. We do not accept returns on reconstituted or opened products due to stability concerns. Read the full returns policy.

Frequently Asked Questions

Ara 290 cibinetide what is it
Ara 290 cibinetide is an 11-amino-acid synthetic peptide engineered from the tissue-protective helix B surface region of erythropoietin. It selectively activates the innate repair receptor (EPOR2-CD131) without stimulating red blood cell production.

Cibinetide ara 290 fda approval status
Cibinetide ara 290 has completed Phase 2 trials for diabetic neuropathy and macular edema but has not received FDA approval. It remains an investigational compound for research use only.

Cibinetide peptide for research
Pure Peptide Factory supplies cibinetide ara 290 as a research-grade peptide for laboratory applications. Each vial contains 10mg lyophilised powder with HPLC verification and a Certificate of Analysis. Minimum order $200 AUD.

Cibinetide ara290 vs ara 290 cibinetide
These are the same compound. Cibinetide is the International Nonproprietary Name (INN). ARA-290 is the research designation. ARA290, ara-290, and cibinetide ara290 all refer to the identical peptide.

Cibinetide phase 3 trials
Cibinetide has not completed Phase 3 trials. It remains in the investigational stage with published Phase 2 data in diabetic neuropathy and macular edema. No Phase 3 completion or FDA approval has been announced.

Is cibinetide ara 290 approved for human use
No. Cibinetide ara 290 is strictly for research and laboratory use. It is not approved by the TGA for human consumption, therapeutic application, or clinical use.

Do you ship outside Australia
Currently, we only ship to Australian addresses. We do not export research compounds due to varying international customs regulations.

How do I verify the purity of my batch
Every batch ships with a unique batch number. Enter this number on our COA lookup page to download the HPLC and mass spec report for your specific vial.